BioNTech Rolls Out a $1 Billion Buyback While Racing Toward Its First Cancer Approval

BioNTech is simultaneously tightening its belt and opening its wallet, a dual move that signals both caution and ambition as the company enters the most data-dense stretch of its post-pandemic life. Since June, the Mainz-based biotech has been buying back up to $1 billion of its own Nasdaq-listed stock, a gesture meant to reassure investors during the messy transition from a Covid powerhouse to a pure-play oncology house. At the same time, the company is slashing costs, closing three sites and cutting about 1,860 jobs, targeting €500 million in annual savings by 2029.

The buyback is already having a modest effect. BioNTech’s shares now change hands at around €82.45, a healthy bounce from the March low of €68.35, though still more than a fifth below the 52-week high. The stock sits just north of its 50-day moving average, while the 200-day line at €85.37 remains tantalisingly close—less than one percentage point away. The relative strength index of 61.6 suggests there is room to run in either direction.

The broader story, however, is about what happens in the lab, not on the trading floor. BioNTech plans to file its first ever US cancer drug application in 2026 for Trastuzumab Pamirtecan, an antibody-drug conjugate developed with DualityBio aimed at advanced endometrial cancer. The FDA has already awarded the candidate both Fast Track and Breakthrough Therapy designations, and the filing is based on a Phase 2 cohort of 145 patients that posted a confirmed response rate of nearly 48 percent, rising to 73.1 percent for patients with the highest HER2 expression. Median progression-free survival stood at just over eight months. The submission still needs the FDA’s final blessing, but it marks the moment when BioNTech’s oncology pivot becomes tangible.

That data-rich second half will feature seven late-stage readouts, including Phase 3 results for Gotistobart in non-small-cell lung cancer and for the mRNA therapy BNT113 against head-and-neck tumours. The company has more than doubled its Phase 2 and Phase 3 oncology studies over the past two years, running over 25 trials today, and has already launched five new pivotal studies for Pumitamig, a candidate targeting breast and stomach cancers.

Gotistobart has already turned heads. In the PRESERVE-003 study, it cut the risk of death by 54 percent relative to standard chemotherapy in certain lung cancer patients. Pumitamig, meanwhile, showed encouraging anti-tumour activity in the ROSETTA Lung-02 trial. The next milestone will be a formal confirmation of the Trastuzumab Pamirtecan filing, followed by Phase 3 interim data for Gotistobart. These two events will effectively decide BioNTech’s market trajectory for the rest of the year.

Should investors sell immediately? Or is it worth buying BioNTech?

Not everyone is convinced the pipeline can deliver on the hype. Analysts at Bernstein SocGen rate the stock at Market Perform, warning that the risk-adjusted peak sales of the pipeline could be roughly 52 percent below the consensus view. The chief worry is the Phase 3 design of Pumitamig, which uses progression-free survival as its primary endpoint. Pfizer, a direct competitor, has chosen overall survival as a dual primary endpoint for its equivalent study, and the FDA considers overall survival the gold standard in lung cancer. That regulatory risk hangs over the programme.

The finances are also under strain. Revenue in the first quarter of 2026 fell to €118.1 million, down from €182.8 million a year earlier, and the net loss swelled to €532 million. The company is burning cash as it invests heavily in oncology and ADC programmes, with no commercial cancer sales expected for several years. Still, the war chest remains formidable: BioNTech reported €16.8 billion in cash and securities at the start of the year, giving it a long runway for its ambitious clinical calendar.

The leadership transition adds another layer of uncertainty. Founders Ugur Sahin and Özlem Türeci announced in March that they would step down from their executive roles by the end of 2026. Alongside the cost cuts and the buyback, the board is clearly trying to project stability during the changing of the guard.

If the second half delivers at least one positive readout, the consensus price target of €106.64—representing about 29 percent upside from current levels—comes back into focus. If the data disappoint, the stock could revisit its 52-week low of €68.35. BioNTech’s year-end narrative will be written not by the buyback or the restructuring, but by the cold numbers from the clinic.